CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.
Identifieur interne : 000084 ( PubMed/Corpus ); précédent : 000083; suivant : 000085CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.
Auteurs : Thomas. Montine ; Min Shi ; Joseph. Quinn ; Elaine. Peskind ; Suzanne Craft ; Carmen Ginghina ; Kathryn. Chung ; Hojoong Kim ; Douglas. Galasko ; Joseph Jankovic ; Cyrus. Zabetian ; James. Leverenz ; Jing ZhangSource :
- Movement disorders : official journal of the Movement Disorder Society ; 2010.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Amyloid beta-Peptides (cerebrospinal fluid), Biomarkers (cerebrospinal fluid), Cognition Disorders (cerebrospinal fluid), Female, Humans, Male, Middle Aged, Parkinson Disease (cerebrospinal fluid), Peptide Fragments (cerebrospinal fluid), tau Proteins (cerebrospinal fluid).
- MESH :
- chemical , cerebrospinal fluid : Amyloid beta-Peptides, Biomarkers, Peptide Fragments, tau Proteins.
- cerebrospinal fluid : Cognition Disorders, Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged.
Abstract
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.
DOI: 10.1002/mds.23287
PubMed: 20818673
Links to Exploration step
pubmed:20818673Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.</title><author><name sortKey="Montine, Thomas J" sort="Montine, Thomas J" uniqKey="Montine T" first="Thomas" last="Montine">Thomas. Montine</name><affiliation><nlm:affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shi, Min" sort="Shi, Min" uniqKey="Shi M" first="Min" last="Shi">Min Shi</name></author><author><name sortKey="Quinn, Joseph F" sort="Quinn, Joseph F" uniqKey="Quinn J" first="Joseph" last="Quinn">Joseph. Quinn</name></author><author><name sortKey="Peskind, Elaine R" sort="Peskind, Elaine R" uniqKey="Peskind E" first="Elaine" last="Peskind">Elaine. Peskind</name></author><author><name sortKey="Craft, Suzanne" sort="Craft, Suzanne" uniqKey="Craft S" first="Suzanne" last="Craft">Suzanne Craft</name></author><author><name sortKey="Ginghina, Carmen" sort="Ginghina, Carmen" uniqKey="Ginghina C" first="Carmen" last="Ginghina">Carmen Ginghina</name></author><author><name sortKey="Chung, Kathryn A" sort="Chung, Kathryn A" uniqKey="Chung K" first="Kathryn" last="Chung">Kathryn. Chung</name></author><author><name sortKey="Kim, Hojoong" sort="Kim, Hojoong" uniqKey="Kim H" first="Hojoong" last="Kim">Hojoong Kim</name></author><author><name sortKey="Galasko, Douglas R" sort="Galasko, Douglas R" uniqKey="Galasko D" first="Douglas" last="Galasko">Douglas. Galasko</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus" last="Zabetian">Cyrus. Zabetian</name></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James" last="Leverenz">James. Leverenz</name></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23287</idno><idno type="RBID">pubmed:20818673</idno><idno type="pmid">20818673</idno><idno type="wicri:Area/PubMed/Corpus">000084</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.</title><author><name sortKey="Montine, Thomas J" sort="Montine, Thomas J" uniqKey="Montine T" first="Thomas" last="Montine">Thomas. Montine</name><affiliation><nlm:affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shi, Min" sort="Shi, Min" uniqKey="Shi M" first="Min" last="Shi">Min Shi</name></author><author><name sortKey="Quinn, Joseph F" sort="Quinn, Joseph F" uniqKey="Quinn J" first="Joseph" last="Quinn">Joseph. Quinn</name></author><author><name sortKey="Peskind, Elaine R" sort="Peskind, Elaine R" uniqKey="Peskind E" first="Elaine" last="Peskind">Elaine. Peskind</name></author><author><name sortKey="Craft, Suzanne" sort="Craft, Suzanne" uniqKey="Craft S" first="Suzanne" last="Craft">Suzanne Craft</name></author><author><name sortKey="Ginghina, Carmen" sort="Ginghina, Carmen" uniqKey="Ginghina C" first="Carmen" last="Ginghina">Carmen Ginghina</name></author><author><name sortKey="Chung, Kathryn A" sort="Chung, Kathryn A" uniqKey="Chung K" first="Kathryn" last="Chung">Kathryn. Chung</name></author><author><name sortKey="Kim, Hojoong" sort="Kim, Hojoong" uniqKey="Kim H" first="Hojoong" last="Kim">Hojoong Kim</name></author><author><name sortKey="Galasko, Douglas R" sort="Galasko, Douglas R" uniqKey="Galasko D" first="Douglas" last="Galasko">Douglas. Galasko</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus" last="Zabetian">Cyrus. Zabetian</name></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James" last="Leverenz">James. Leverenz</name></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="e-ISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Amyloid beta-Peptides (cerebrospinal fluid)</term><term>Biomarkers (cerebrospinal fluid)</term><term>Cognition Disorders (cerebrospinal fluid)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (cerebrospinal fluid)</term><term>Peptide Fragments (cerebrospinal fluid)</term><term>tau Proteins (cerebrospinal fluid)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Amyloid beta-Peptides</term><term>Biomarkers</term><term>Peptide Fragments</term><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20818673</PMID><DateCreated><Year>2010</Year><Month>11</Month><Day>11</Day></DateCreated><DateCompleted><Year>2011</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>15</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.</ArticleTitle><Pagination><MedlinePgn>2682-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23287</ELocationID><Abstract><AbstractText>We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.</AbstractText><CopyrightInformation>© 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ginghina</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hojoong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zabetian</LastName><ForeName>Cyrus P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025327</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES004696</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS060252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017-10</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P42 ES004696</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P42 ES004696-235897</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136-25</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684-02</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025327</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025327-05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033398-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057567-02</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS060252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS060252-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1984 Jul;34(7):939-44</RefSource><PMID Version="1">6610841</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Intern Med. 2004 Sep;256(3):183-94</RefSource><PMID Version="1">15324362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1993 Nov;43(11):2412-4</RefSource><PMID Version="1">8232972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2007 Mar;64(3):343-9</RefSource><PMID Version="1">17210801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Aug 14;69(7):631-9</RefSource><PMID Version="1">17698783</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</RefSource><PMID Version="1">17542011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 2008 Apr;129(4):526-9</RefSource><PMID Version="1">18343778</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2008 Aug;7(8):704-14</RefSource><PMID Version="1">18635019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2008 Nov 15;64(10):850-5</RefSource><PMID Version="1">18395699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Apr;65(4):403-13</RefSource><PMID Version="1">19296504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2009 Jul 22;302(4):385-93</RefSource><PMID Version="1">19622817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Jul 28;73(4):294-301</RefSource><PMID Version="1">19636049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Nov 15;24(15):2203-10</RefSource><PMID Version="1">19795497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2009 Dec;66(12):1557-62</RefSource><PMID Version="1">20008664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Jan 5;74(1):77-84</RefSource><PMID Version="1">20038776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO Mol Med. 2009 Nov;1(8-9):371-80</RefSource><PMID Version="1">20049742</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2010 Feb 15;289(1-2):18-22</RefSource><PMID Version="1">19733364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2010 Mar;133(Pt 3):713-26</RefSource><PMID Version="1">20157014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016229">Amyloid beta-Peptides</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016875">tau Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS207952</OtherID><OtherID Source="NLM">PMC2978754</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23287</ArticleId><ArticleId IdType="pubmed">20818673</ArticleId><ArticleId IdType="pmc">PMC2978754</ArticleId><ArticleId IdType="mid">NIHMS207952</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000084 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000084 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20818673
|texte= CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20818673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |